{"title":"Yiran Zhu 等人对临床与转化医学《LncRNA LINC00942 通过抑制 MSI2 降解增强 c-Myc mRNA 稳定性促进胃癌化疗耐药性》一文的勘误。","authors":"Yiran Zhu, Bingluo Zhou, Xinyang Hu, Shilong Ying, Qiyin Zhou, Wenxia Xu, Lifeng Feng, Tianlun Hou, Xian Wang, Liyuan Zhu, Hongchuan Jin","doi":"10.1002/ctm2.70106","DOIUrl":null,"url":null,"abstract":"<p>Following the publication of the original article,<sup>1</sup> the authors identified a minor error in Figure 1G, where the western blot image of the a-tubulin reference for SGC-R was inadvertently duplicated with that of BGC-R. We sincerely apologise for any confusion this may have caused. It is important to note that this error did not affect the overall results, as the cleavage of PARP1 and caspase-3 was appropriately supported by the levels of total PARP1 and caspase-3.</p><p>We have located the original western blot data for the a-tubulin reference for SGC-R and have made the necessary corrections to Figure 1G. Importantly, we assure readers that this erratum does not impact the conclusions or descriptions presented in the article.</p><p>1. Zhu, Y., Zhou, B., Hu, X., Ying, S., Zhou, Q., Xu, W., Feng, L., Hou, T., Wang, X., Zhu, L., & Jin, H. (2022, Jan). LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. <i>Clin Transl Med, 12</i>(1), e703. https://doi.org/10.1002/ctm2.703</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"14 11","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70106","citationCount":"0","resultStr":"{\"title\":\"Erratum for the Clinical and Translational Medicine ‘LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability’ by Yiran Zhu et al.\",\"authors\":\"Yiran Zhu, Bingluo Zhou, Xinyang Hu, Shilong Ying, Qiyin Zhou, Wenxia Xu, Lifeng Feng, Tianlun Hou, Xian Wang, Liyuan Zhu, Hongchuan Jin\",\"doi\":\"10.1002/ctm2.70106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Following the publication of the original article,<sup>1</sup> the authors identified a minor error in Figure 1G, where the western blot image of the a-tubulin reference for SGC-R was inadvertently duplicated with that of BGC-R. We sincerely apologise for any confusion this may have caused. It is important to note that this error did not affect the overall results, as the cleavage of PARP1 and caspase-3 was appropriately supported by the levels of total PARP1 and caspase-3.</p><p>We have located the original western blot data for the a-tubulin reference for SGC-R and have made the necessary corrections to Figure 1G. Importantly, we assure readers that this erratum does not impact the conclusions or descriptions presented in the article.</p><p>1. Zhu, Y., Zhou, B., Hu, X., Ying, S., Zhou, Q., Xu, W., Feng, L., Hou, T., Wang, X., Zhu, L., & Jin, H. (2022, Jan). LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. <i>Clin Transl Med, 12</i>(1), e703. https://doi.org/10.1002/ctm2.703</p>\",\"PeriodicalId\":10189,\"journal\":{\"name\":\"Clinical and Translational Medicine\",\"volume\":\"14 11\",\"pages\":\"\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70106\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70106\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70106","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Erratum for the Clinical and Translational Medicine ‘LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability’ by Yiran Zhu et al.
Following the publication of the original article,1 the authors identified a minor error in Figure 1G, where the western blot image of the a-tubulin reference for SGC-R was inadvertently duplicated with that of BGC-R. We sincerely apologise for any confusion this may have caused. It is important to note that this error did not affect the overall results, as the cleavage of PARP1 and caspase-3 was appropriately supported by the levels of total PARP1 and caspase-3.
We have located the original western blot data for the a-tubulin reference for SGC-R and have made the necessary corrections to Figure 1G. Importantly, we assure readers that this erratum does not impact the conclusions or descriptions presented in the article.
1. Zhu, Y., Zhou, B., Hu, X., Ying, S., Zhou, Q., Xu, W., Feng, L., Hou, T., Wang, X., Zhu, L., & Jin, H. (2022, Jan). LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. Clin Transl Med, 12(1), e703. https://doi.org/10.1002/ctm2.703
期刊介绍：
Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
